KLOW
A multi-peptide blend combining anti-inflammatory and healing peptides for combined effects on tissue repair, inflammation, and barrier function.
Molecular Structure
Amino Acid Sequence
Molecular Formula
Molecular Weight
Half-Life
CAS Number
What is KLOW?
KLOW is a multi-peptide combination product whose name is derived from the first letters of its constituent peptides. The first two letters consistently refer to KPV (a small anti-inflammatory tripeptide derived from α-MSH) and LL-37 (the human cathelicidin antimicrobial peptide). The remaining components — represented by the O and W in the acronym — can vary between suppliers, with different specific peptides used in those positions depending on the manufacturer.
KLOW is notable in research because the conceptual basis combines targeting multiple aspects of tissue health simultaneously through complementary peptides. The consistent KPV and LL-37 components provide anti-inflammatory activity (through NF-κB inhibition) and antimicrobial/immunomodulatory effects respectively. The variable O and W components can target additional repair or signaling pathways depending on the formulation. Because KLOW formulations vary between suppliers, researchers using a specific KLOW product should verify the exact composition with their supplier before any research application.
Mechanism of action
KLOW’s mechanisms of action have been investigated across multiple pathways:
- KPV — NF-κB pathway inhibition: The KPV component inhibits activation of nuclear factor kappa B, reducing production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6.
- LL-37 — Direct antimicrobial activity: The LL-37 component’s amphipathic α-helical structure produces broad-spectrum antimicrobial activity through membrane permeabilization of bacterial and other microbial pathogens.
- LL-37 — Immunomodulation: Research has documented effects on immune cells including neutrophils, monocytes, and dendritic cells, including chemotaxis modulation and effects on adaptive immune response development.
- Complementary mechanism rationale: The combination targets inflammation reduction (KPV), antimicrobial defense (LL-37), and additional repair or signaling effects from the variable components, theoretically producing more comprehensive effects than single-peptide approaches.
- PEPT1-mediated tissue delivery: The KPV component is absorbed via the peptide transporter 1 expressed on epithelial cells, providing a mechanism for direct delivery to mucosal tissue.
These pathways are characterized primarily in preclinical research on the individual component peptides; combination-specific mechanism research is limited.
Research applications
KLOW has been investigated across several research domains, with the most active areas including:
- Inflammatory conditions research: The anti-inflammatory effects of the consistent KPV and LL-37 components have driven research interest in inflammatory conditions including inflammatory bowel disease, certain skin conditions, and mucosal inflammation.
- Tissue repair research: The combination of immunomodulation, antimicrobial activity, and potential additional repair signals positions KLOW-type blends for research in wound healing and tissue repair contexts.
- Barrier function research: Both KPV and LL-37 have roles in epithelial barrier function. Research has examined applications in conditions affecting mucosal barriers including gastrointestinal and respiratory contexts.
- Comparative blend research: Studies have examined the rationale for multi-peptide blends versus single-peptide approaches, with KLOW serving as an example of the multi-peptide combination strategy in regenerative research.
- Supplier-specific formulation research: Because KLOW formulations vary, research on specific KLOW products examines the particular peptides included by the manufacturer rather than a standardized formulation, requiring researchers to verify composition before application.
This compound is intended for laboratory research use only. It has not been approved for human therapeutic use by any regulatory agency.
Storage & reconstitution
In lyophilized form, KLOW is typically stored at -20°C, protected from light. Properly stored lyophilized peptides remain stable for 24 months or longer. The stability of a blend reflects the least stable component, so blends with rapidly-degrading components may have shorter usable life than individual peptide entries.
Once reconstituted with bacteriostatic water for injection, solutions should be stored refrigerated at 2-8°C and used within 28 days. Avoid repeated freeze-thaw cycles, which can degrade peptide structure and reduce activity.
Visual inspection should be performed before each use. The reconstituted solution should be clear and colorless. Reject any solution that appears cloudy, discolored, or contains visible particulate matter.
For step-by-step reconstitution calculations, see our reconstitution calculator.
For laboratory research use only. The compound described on this page is intended exclusively for in vitro research and laboratory experimentation by qualified researchers and is not for human or veterinary use. It is not a drug, food, dietary supplement, or cosmetic, and has not been approved by the FDA, Health Canada, EMA, or any other regulatory authority for the diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition. The information provided on this page is for educational and reference purposes only and does not constitute medical advice. By accessing this content you confirm that you are a qualified researcher purchasing for legitimate laboratory purposes.